Related Experiment Video
Updated: Jul 6, 2026
05:51
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
Antiparkinsonian medication and pathological gambling
1Institute of Psychiatry, King's College, London, England. m.lader@iop.kcl.ac.uk
CNS Drugs
|April 11, 2008
Summary
Dopamine-based Parkinson's disease medications can cause impulse control disorders like pathological gambling in up to 7% of users. Treatment involves dose reduction or switching medications, though Parkinson's symptoms may worsen.
Area of Science:
- Neurology
- Pharmacology
- Behavioral Science
Background:
- Parkinson's disease is commonly treated with dopaminergic agents.
- These medications can lead to behavioral abnormalities, including impulse control disorders (ICDs).
- Pathological gambling is a significant ICD, disrupting personal and occupational life.
Purpose of the Study:
- To review the association between dopaminergic agents and pathological gambling in Parkinson's disease patients.
- To discuss the incidence, potential contributing factors, and management strategies for this adverse effect.
Main Methods:
- Literature review of studies on dopaminergic agents and behavioral abnormalities.
- Analysis of reported cases and regulatory warnings regarding pathological gambling.
- Discussion of proposed mechanisms and treatment approaches.
Main Results:
- Up to 7% of dopaminergic agent users may develop pathological gambling.
- Pramipexole and possibly ropinirole are frequently implicated.
- Treatment involves medication adjustment, potentially worsening Parkinson's symptoms.
Conclusions:
- Pathological gambling is a recognized risk associated with dopaminergic therapy for Parkinson's disease.
- Excessive dopaminergic stimulation is the suspected mechanism.
- Careful patient monitoring and management are essential.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
01:28Drugs Acting on Autonomic Ganglia: Blockers
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups: